FIXX - ホモロジ―・メディシンズ （Homology Medicines Inc.） ホモロジ―・メディシンズFIXXのチャート
FIXXの企業情報
| symbol | FIxx |
|---|---|
| 会社名 | Homology Medicines Inc （ホモロジ―・メディシンズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Homology Medicines Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver central nervous system (CNS) bone marrow lung and the eye. The Company’s lead product candidate HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target via a single intravenous injection a wide range of disease-relevant tissues including the liver central nervous system or CNS bone marrow lung muscle and eye across both modalities - gene editing and gene therapy. ホモロジ―・メディシンズは米国のバイオ医薬品企業。遺伝病の患者に対する遺伝子医薬品の開発に従事する。同社独自のプラットフォ―ムにより、ヒト造血幹細胞由来のアデノ随伴ウイルスベクタ―を利用して、遺伝子治療や遺伝子編集に取り組む。同社は、単一の疾患遺伝子に起因する一因性疾患に焦点を当てる。本社所在地はマサチュ―セッツ州ベッドフォ―ド。 Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology's proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its family of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. |
| 本社所在地 | 45 Wiggins Avenue Bedford MA 01730 USA |
| 代表者氏名 | Arthur Tzianabos アーサー・チアナボス |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 857-305-1825 |
| 設立年月日 | 42064 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 67人 |
| url | www.homologymedicines.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fixx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） ー |
| 終値（lastsale） | 20.02 |
| 時価総額（marketcap） | 750242472.98 |
| 時価総額 | 時価総額（百万ドル） 746.86980 |
| 売上高 | 売上高（百万ドル） -- |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 491.36170 |
| 当期純利益 | 当期純利益（百万ドル） -- |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Homology Medicines Inc revenues increased from $0K to $1.7M. Net loss increased from $11.6M to $23.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $6.8M to $18M (expense) General and administrative - Balancing v increase from $3.8M to $7.7M (expense). |
FIXXのテクニカル分析
FIXXのニュース
Homology Medicines GAAP EPS of -$0.50 beats by $0.04, revenue of $0.8M misses by $0.21M 2023/05/11 21:20:20 Seeking Alpha
Homology Medicines press release (FIXX): Q1 GAAP EPS of -$0.50 beats by $0.04.Revenue of $0.8M (flat Y/Y) misses by $0.21M.As of March 31, 2023, Homology had approximately…
Homology Medicines: Q1 Earnings Snapshot 2023/05/11 20:24:35 WTOP
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Homology Medicines Inc. (FIXX) on Thursday reported a loss of $28.8 million…
Homology Medicines PT Lowered to $2 at Stifel 2023/03/10 14:20:12 Investing.com
https://www.investing.com/news/pro/homology-medicines-pt-lowered-to-2-at-stifel-432SI-3027690
Homology Medicines GAAP EPS of -$0.60 misses by $0.07, revenue of $0.82M misses by $0.1M 2023/03/09 22:55:07 Seeking Alpha
Homology Medicines press release (NASDAQ:FIXX): Q4 GAAP EPS of -$0.60 misses by $0.07.Revenue of $0.82M (+2.5% Y/Y) misses by $0.1M.
Homology Medicines: Q4 Earnings Snapshot 2023/03/09 22:49:27 WTOP
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Homology Medicines Inc. (FIXX) on Thursday reported a loss of $34.3 million…
Homology Medicines PT Lowered to $2 at Stifel 2023/03/10 14:20:12 Investing.com
https://www.investing.com/news/pro/homology-medicines-pt-lowered-to-2-at-stifel-432SI-3027690
Homology Medicines GAAP EPS of -$0.60 misses by $0.07, revenue of $0.82M misses by $0.1M 2023/03/09 22:55:07 Seeking Alpha
Homology Medicines press release (NASDAQ:FIXX): Q4 GAAP EPS of -$0.60 misses by $0.07.Revenue of $0.82M (+2.5% Y/Y) misses by $0.1M.
Homology Medicines: Q4 Earnings Snapshot 2023/03/09 22:49:27 WTOP
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Homology Medicines Inc. (FIXX) on Thursday reported a loss of $34.3 million…
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights 2023/03/09 21:05:00 GlobeNewswire
- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening -
Homology Medicines gets new chief medical officer 2023/03/09 13:37:13 Seeking Alpha
Genetic medicines company, Homology Medicines (FIXX) announced that Julie Jordan, M.D., has been promoted to Chief Medical Officer. Previously, Dr
Homology Medicines PT Lowered to $2 at Stifel 2023/03/10 14:20:12 Investing.com
https://www.investing.com/news/pro/homology-medicines-pt-lowered-to-2-at-stifel-432SI-3027690
Homology Medicines GAAP EPS of -$0.60 misses by $0.07, revenue of $0.82M misses by $0.1M 2023/03/09 22:55:07 Seeking Alpha
Homology Medicines press release (NASDAQ:FIXX): Q4 GAAP EPS of -$0.60 misses by $0.07.Revenue of $0.82M (+2.5% Y/Y) misses by $0.1M.
Homology Medicines: Q4 Earnings Snapshot 2023/03/09 22:49:27 WTOP
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Homology Medicines Inc. (FIXX) on Thursday reported a loss of $34.3 million…